35 benchmarked salary cells across MedTech, Pharma, MSL and Aesthetics — the most resilient hiring market in this guide, with three sub-segments that pay by entirely different rules.
← All Industries Next: B2B →
UK Healthcare, Aesthetics & MedTech sales salaries in 2026 sit on top of the most resilient hiring market in this guide — Nursing, Medical and Care was one of only two job categories with rising temporary demand in the May 2026 KPMG/REC Report on Jobs, against a backdrop of permanent placements falling at the fastest rate since January nationally. The sector breaks into three sub-segments with materially different reward shapes: MedTech / medical devices (capital equipment plus consumables, bonus-heavy with uncapped commission overlay); Pharma / biotech / life sciences including the regulatorily-protected Medical Science Liaison function; and Aesthetics (manufacturer-side National Account Managers plus private-pay clinic-side Patient Coordinators and Clinic Managers, with the Lorena Cosmetics rebuild as the structural 2026 story). This chapter sets out 35 benchmarked cells — base salary by seniority level and UK region — for SDR / Field Clinical Specialist / Patient Coordinator, Territory Manager / NAM, Senior Territory Manager / MSL / Aesthetic AM, Regional Sales Manager / Head of Aesthetics, and Commercial Director / VP Sales / CCO roles. Compiled May 2026 against ABHI sector data, ONS earnings data, RepVue UK MedTech rep dataset, Glassdoor MSL and aesthetics-manufacturer self-reports, and live job advertisements.
Healthcare, Aesthetics and MedTech is the sector that quietly defies almost every macro headline this guide has surfaced. While the May 2026 KPMG/REC Report on Jobs records permanent placements falling at the fastest rate since January across the UK economy, the same report flags Nursing, Medical and Care as one of only two categories with rising demand for temporary staff in April 2026. Healthcare hiring is not booming, but it is the most resilient hiring market in this guide — and the commercial sales workforce sitting alongside the clinical workforce benefits from the same underlying demand pull. The wider context sits inside the 2026 UK Sales Salary Guide's cross-sector framework.
The sector breaks into three sub-segments that share a customer base but behave very differently on reward design, talent flow and 2026 hiring mood. Combined, they employ a UK commercial sales workforce in the high tens of thousands.
Two macro forces complete the 2026 sector picture. First, the Iran / Hormuz / Red Sea disruption is mildly net-negative for MedTech — Asian medical device imports transiting Suez and Hormuz are being hit by 25–40% Asia–Europe rate increases and war risk surcharges of $1,500–$4,000 per container, with Stryker, Medtronic, J&J and Boston Scientific UK supply chains all exposed. Crucially, aesthetics is less exposed because the injectable supply chain runs Switzerland (Galderma), Ireland (Allergan / Westport Botox manufacturing), Germany (Merz) and the UK domestic side (Sinclair Pharma's Chester operation) — none of which transit Suez or Hormuz. Second, the collapse and rescue of Sk:n / The Harley Medical Group is the structural sector event of the past 18 months: SKN Group ceased trading on 17 July 2024 with all 70 clinics shuttered and approximately 450 practitioners displaced. In December 2024 Lorena Cosmetics Holdings SPV (controlled by Optical Express founder David Moulsdale) acquired and relaunched approximately 30 clinic locations, with flagships at London's Harley Street and Glasgow's St. Vincent Street. The Lorena rebuild is the dominant aesthetics-private-pay employment story of 2026 — new commercial and clinic-management hiring is happening from a re-set baseline, not from greenfield growth.
The aggregate hiring read for 2026: resilient on demand, structurally tilted toward temporary and contract for primary-care reps and aesthetics practitioners, with permanent leadership hiring concentrated at Senior IC and above where the regulatory shift creates a premium for genuine commercial-clinical sophistication.
The aesthetics private-pay clinic-side warrants one extra note for hiring managers benchmarking against this chapter: the practitioner-side outside option is a wage floor that salaried Patient Coordinator and Clinic Manager hiring is competing against. Independent self-employed Level 7 injectable practitioners working from premium clinic locations at 20 billable hours per week can gross £230K+ annually, with net income typically £150–£180K after rent, insurance, marketing and stock (Cosmetic College UK Aesthetics Salary Benchmark, January 2026). That figure does not sit in the salary tables below — those are calibrated for salaried / PAYE commercial roles, not self-employed practitioner P&L outcomes — but every aesthetics hiring manager will recognise the gravitational pull it exerts on the salaried clinic-side talent market.
All figures are GBP. Mid = market median for the cell; low/high reflect the typical interquartile spread of advertised and placed roles. This chapter shows base salary ranges; OTE multipliers and bonus structures are quoted in the reading note for each level. The chapter-level OTE multiplier runs 1.10–1.15× at Entry, 1.25–1.40× at Mid IC (capital-equipment commission overlay), 1.30–1.45× at Senior IC (the widest spread in the chapter as MSL, MedTech capital-equipment and aesthetics-manufacturer reward shapes overlap), 1.25–1.35× at Management, 1.30–1.50× at Senior Leadership.
Three distinct entry routes converge on this seniority band. MedTech entry is structured around graduate clinical-specialist programmes — Boston Scientific Hemel Hempstead's Field Clinical Specialist Graduate (Cardio) is a live London anchor; Stryker UK runs Sales Associate routes from Ipswich (Trauma, Mid + South Essex / East Suffolk) and Preston (Territory Sales, Upper Extremities, North West). Pharma entry runs through the major schemes at GSK, AstraZeneca, Pfizer, Sanofi and Roche UK, typically £32–38K base. Aesthetics clinic-side entry is the Patient Coordinator / Treatment Coordinator route — a Knightsbridge doctor-led clinic role at £30–40K + commission (February 2026 live ad) is the published anchor. The Lorena Cosmetics rebuild has created new entry-level Clinic Coordinator vacancies at the relaunched ~30 sites, with Glasgow St Vincent St and London Harley Street as flagships.
| Region | Base low | Base mid | Base high |
|---|---|---|---|
| London & South East | £30K | £35K | £42K |
| East of England | £30K | £34K | £40K |
| West Midlands | £28K | £32K | £38K |
| East Midlands | £27K | £31K | £36K |
| North of England | £26K | £30K | £36K |
| Scotland & NI | £25K | £29K | £34K |
| South West & Wales | £25K | £28K | £34K |
Reading note. OTE multiplier at this level is 1.10–1.15× base — quarterly performance bonuses for the graduate-scheme intake, commission overlay for the Patient Coordinator route, neither for MSL trainees. Cars and allowances uncommon at Entry except for the Stryker-type Sales Associate field-rep route. Cambridge and Stevenage anchor East of England's slight premium over the Midlands at this level — biotech graduate-scheme intake clusters here.
The cell where most MedTech and aesthetics-manufacturer commercial sales careers actually live. The cleanest 2026 anchors are the Territory Manager ads sampled through Q1–Q2 2026: Territory Manager (Infection Prevention & Surgical Solutions, East Scotland & NE England) at £42–45K base + 20%+ bonus + car (Feb 2026); Territory Manager (Respiratory Devices, South Wales & Bristol) at £50K + bonus + car; Surgical Sales Specialist (Minimally Invasive Surgery, East Anglia) at £50K + £22K bonus + fully expensed hybrid / EV car; Senior Territory Sales Manager (Northern Region, global health manufacturer) at £50–64K + £20–25K OTE + car. Galderma UK's National Account Manager at £83,786 Glassdoor average (March 2026) and Allergan Aesthetics Strategic Account Manager (eight UK reports on Glassdoor) both sit at the top of this cell or into Senior IC depending on patch.
| Region | Base low | Base mid | Base high |
|---|---|---|---|
| London & South East | £46K | £55K | £68K |
| East of England | £46K | £54K | £66K |
| West Midlands | £44K | £52K | £62K |
| East Midlands | £42K | £50K | £60K |
| North of England | £40K | £48K | £58K |
| Scotland & NI | £38K | £46K | £55K |
| South West & Wales | £38K | £46K | £55K |
Reading note. OTE multiplier 1.25–1.40× base. Bonus typically 20–30% of base; uncapped commission overlay common on capital-equipment territories. Car or car allowance near-universal at Territory Manager level — the field role pattern demands it. Allowances £5,500–£7,500 at Mid IC. The Cambridge biotech cluster keeps East of England within £1–2K of London & South East at this level — the cluster effect that widens at Senior IC.
The cell with the widest spread in this entire chapter — and the most important to read with sub-segment composition in mind. Three reward shapes overlap here: capital-equipment Senior Territory Reps with heavy commission accelerators; aesthetics-manufacturer Strategic Account Managers and KOL Liaison roles; and the MSL function with its regulatory wrapper. East of England sits at London & South East parity at this level — the Cambridge biotech cluster (AstraZeneca Cambridge, Mundipharma, GSK Stevenage R&D-adjacent commercial) is the strongest non-London anchor in any sector in this guide outside the Energy offshore-wind pattern and the Logistics Golden Triangle. The Strategic BDM (Wound Care, SE & SW) live ad at £60K + £13K OTE + £625 car allowance + £13K commission (Q2 2026) sits in this cell.
| Region | Base low | Base mid | Base high |
|---|---|---|---|
| London & South East | £58K | £72K | £90K |
| East of England | £58K | £72K | £88K |
| West Midlands | £54K | £66K | £82K |
| East Midlands | £52K | £64K | £78K |
| North of England | £50K | £62K | £76K |
| Scotland & NI | £48K | £60K | £74K |
| South West & Wales | £48K | £60K | £72K |
Reading note. OTE multiplier 1.30–1.45× base. The wide cell spread (London & SE high of £90K base, OTE up to £135K) reflects the capital-equipment commission overlay specifically; the AstraZeneca MSL median of £70,633 sits cleanly inside this cell at a lower variable component, while a Galderma UK Senior NAM or Allergan Aesthetics Strategic AM sits near the top. Car or allowance universal; £6,500–£9,500 range. RepVue's UK Medical Device Sales Representative dataset (April 2026 update) puts median base for the global role at ~$70K and median OTE at $165K — close to the UK pattern when adjusted, and implies approximately 50% of total cash reward comes through variable comp for MedTech reps, comparable to mid-SaaS and well above FMCG NAM.
The management cell where listed-group LTIPs start to become material to total reward. Stryker UK, Medtronic UK, J&J Medical UK, Smith+Nephew, Boston Scientific UK and AbbVie / Allergan UK all run RSM-tier LTIP grants for the management cohort. On the aesthetics manufacturer side, Galderma's Regional Business Manager (Aesthetics, South West / Midlands UK) Q1 2026 ad sits squarely in this band. On the clinic-side, the Sk:n Manchester Bridgewater Clinic Manager / Hospital Manager listing referencing a Divisional Support Manager reporting line is a Lorena Cosmetics post-relaunch role that confirms how the rebuild has restructured the management tier. West Midlands holds a slight premium versus other sectors at this level because of the cluster strength noted above.
| Region | Base low | Base mid | Base high |
|---|---|---|---|
| London & South East | £75K | £92K | £118K |
| East of England | £72K | £88K | £112K |
| West Midlands | £68K | £84K | £105K |
| East Midlands | £65K | £80K | £100K |
| North of England | £62K | £78K | £98K |
| Scotland & NI | £58K | £74K | £92K |
| South West & Wales | £58K | £74K | £90K |
Reading note. OTE multiplier 1.25–1.35× base. Bonus typically 25–35% of base; small LTIP component at listed groups. Car or allowance universal; £6,500–£10,500 range. Specialist aesthetics-clinic-chain regional management is often paid lower base but supplemented with treatment-revenue bonuses.
The cell with the widest absolute spread anywhere in this chapter, driven by the LTIP component that becomes a meaningful slice of total reward at this level. The Allergan Aesthetics UK Senior Manager Glassdoor estimate of £299,828 is the documented premium anchor — small sample but corroborated by cross-references to AbbVie UK senior commercial bands and to published 2025/26 MedTech Director benchmarks. Senior leadership total package (base + cash bonus + LTIP four-year vesting) at the listed global MedTech groups (Stryker UK, J&J Medical, Smith+Nephew, Boston Scientific, Medtronic UK) at Country Director / VP Sales UK level can comfortably exceed £400K all-in. Private-pay clinic chain CCO / MD roles at the largest UK groups (Lorena Cosmetics post-Dec 2024 relaunch, Therapie Clinic UK / Ireland MD, The Private Clinic Group CCO, The Dermatology Partnership CCO) sit in the £180–280K total range.
| Region | Base low | Base mid | Base high |
|---|---|---|---|
| London & South East | £120K | £160K | £210K |
| East of England | £115K | £155K | £200K |
| West Midlands | £105K | £140K | £180K |
| East Midlands | £95K | £128K | £165K |
| North of England | £92K | £125K | £160K |
| Scotland & NI | £88K | £118K | £150K |
| South West & Wales | £85K | £115K | £148K |
Reading note. OTE multiplier 1.30–1.50× base. Cash bonus 35–50% of base at director level; LTIP material at all listed groups. Car or allowance universal at this level; £7,500–£13,500 range. Sample at this level outside London & South East and West Midlands is genuinely thin and is flagged honestly in the cell-level confidence ratings.
This chapter contains the highest single OTE multiplier in the guide's Shape B group at 1.34× (Senior IC) — modestly above Energy and FMCG at 1.30×, well above Construction at 1.25×, and second only to Technology & SaaS outside the B2B band. But the chapter's distinguishing features are the regional cluster pull-ups and the aesthetics regulatory shift. Three regional features warrant explicit benchmarking attention.
London & South East includes the M4 corridor at 15–22% premium. Stryker UK Newbury, J&J Medical Wokingham, Edwards Lifesciences Newbury, Smith+Nephew Watford, Boston Scientific Hemel Hempstead, Karl Storz Slough and Convatec Reading all sit in this band. The cluster premium is tighter than Tech (+18–25%) but wider than FMCG (+10–15%) — the field-sales workforce that visits NHS hospitals and private hospitals from Newbury through Reading down to Wokingham is paid for the patch with a meaningful London / M4 weighting. The Harley Street / Knightsbridge aesthetics private-pay flagship cluster sits inside this London & SE premium too.
East of England sits at London & SE parity at Senior IC, driven by the Cambridge biotech cluster. AstraZeneca Cambridge, Mundipharma, GSK Stevenage R&D-adjacent commercial roles, ARM Cambridge's medical-devices subsidiary, and Domino Printing's medical division all anchor a real commercial talent market that is genuinely competitive with London at Senior IC and tightens to a small gap at Management. This mirrors the Energy offshore-wind cluster pattern rather than the Logistics Golden Triangle pattern.
West Midlands maintains a small premium above the foundation baseline across Mid IC, Management and Senior Leadership — the only sector in this guide outside Construction where this happens consistently. The reason is the cluster scale: 14,000+ medical-devices jobs, £6bn in combined turnover, and three active live-growth nodes (Birmingham Health Innovation Campus, Birmingham Knowledge Quarter, Arden Cross). The MedTech HTQ rollout from September 2026 is specifically intended to plug an estimated 145,000-jobs skills shortage by 2035.
Hiring implication. Hiring managers building UK MedTech commercial teams in 2026 should explicitly consider Birmingham as a base alongside London / Reading / Newbury, particularly for Senior Territory Managers and Regional Sales Managers covering the Midlands hospital network.
For the full cross-sector picture — OTE multipliers across all nine sectors, reward shapes, and which macro winds are blowing in each — see the Cross-Cutting Analysis chapter.
Patient Coordinator commission is the single most aggressive variable structure in this chapter — typically a percentage of treatment revenue booked, ranging from 5–15% on premium injectables packages. A high-converting Patient Coordinator at a busy London Harley Street doctor-led clinic can earn variable comp equivalent to 80–120% of base.
Clinic Manager bonuses are tied to clinic P&L; Regional Manager bonuses to multi-site treatment-revenue growth. Targets vary widely by chain; the Lorena Cosmetics rebuild is reportedly running with conservative Year 1 target attainment expectations (60–70% inferred from market evidence) while the chain reconstructs patient pipelines.
Quota attainment inferences across the chapter:
Top performer headroom: 130–180% of OTE in commission-heavy MedTech and aesthetics clinic-side roles; modest in MSL; up to 200%+ in MedTech capital-equipment territories with strong accelerator brackets.
Company car or car allowance is near-universal at Mid IC and above across all three sub-segments. The 2026 BIK regime makes the EV salary-sacrifice route the default — confirmed at AbbVie UK, Stryker UK, Medtronic UK, J&J Medical, Smith+Nephew, Boston Scientific UK, GSK, AstraZeneca, Pfizer UK, Galderma UK and Allergan Aesthetics through recent live-ad and Glassdoor benefit-disclosure patterns. Allowance bands as shown in the salary tables: £5,500–£7,500 at NAM / Territory Manager, scaling to £9,000–£13,500 at Senior Leadership. Hybrid and EV company cars are the dominant package option in the MedTech live ads sampled through Q1–Q2 2026 — the Surgical Sales Specialist East Anglia ad explicitly offers a "fully expensed hybrid / electric car."
Private medical insurance is universal at Mid IC+ across MedTech and Pharma (employers in this sector cannot credibly offer their workforce anything less). Clinic-side aesthetics employers vary — the Lorena Cosmetics / Sk:n re-launched chain offers PMI, free eye tests, laser eye surgery and intraocular lens surgery as part of the wider Optical Express group benefits package.
Stryker UK Newbury, J&J Medical Wokingham, Edwards Lifesciences Newbury, Smith+Nephew Watford (plus the Hull manufacturing site), Boston Scientific Hemel Hempstead, Karl Storz Slough, Convatec Reading. 15–22% premium above the foundation baseline across IC and Management cells. The Harley Street / Knightsbridge aesthetics private-pay flagship cluster sits inside this London & SE premium too — the Knightsbridge Patient Coordinator live ad and the Sk:n Harley Street flagship (Lorena Cosmetics relaunched site) both fit cleanly inside the upper end of the London & SE band at each level.
AstraZeneca Cambridge, Mundipharma, GSK Stevenage R&D-adjacent commercial roles, ARM Cambridge's medical-devices subsidiary, Domino Printing's medical division. Sits at London & SE parity at Senior IC; tightens to a small gap at Management. Hiring managers in East of England should expect to pay London & SE rates for Senior MedTech and Pharma reps and Cambridge-located MSLs.
14,000+ medical-devices jobs, £6bn in combined turnover, three active live-growth nodes (Birmingham Health Innovation Campus, Birmingham Knowledge Quarter, Arden Cross). The only sector in this guide outside Construction where the West Midlands consistently sits above the foundation baseline. The MedTech HTQ rollout from September 2026 (BMet / Pearson / West Midlands Combined Authority / Skills England partnership) will increase entry-level talent supply but is unlikely to soften Mid IC or higher cells through 2026 itself.
Smith+Nephew Hull (orthopaedics and wound-care manufacturing legacy), B. Braun Sheffield (ostomy and IV access), the Manchester pharma corridor (residual GSK / AstraZeneca operations plus a healthy independent biotech and digital-health start-up scene), and post-July 2024 the reopened Sk:n Manchester Bridgewater pilot site under Lorena Cosmetics. NW / Yorkshire is genuinely well-supplied at IC and Management level.
Moderate discount to baseline across most cells, with the Glasgow Sk:n St Vincent Street flagship under Lorena Cosmetics as the principal aesthetics-private-pay anchor, Edinburgh-based MedTech territory roles as the principal MedTech anchor, and a thin but emerging biotech and digital-health leadership scene in Edinburgh. The Scottish Parliament's March 2026 Cosmetic Procedures (Licensing) Bill is reshaping practitioner hiring at the Glasgow flagship specifically.
The thinnest region for this sector at Senior Leadership. A Bristol-based Respiratory Devices South Wales / Bristol live ad at £50K + bonus + car is the cleanest Mid IC anchor; Galderma's Regional Business Manager (Aesthetics, South West) Q1 2026 ad is the cleanest Management anchor. Benchmark Senior Leadership cells against published 2025/26 executive-search data rather than against the live-ad market for this region.
The 2026 sector hiring market is shaped by five forces hiring managers will recognise from their pipelines and pay-negotiation conversations.
Force 1 — Healthcare-temp resilience. The KPMG/REC May 2026 Report on Jobs flagging Nursing / Medical / Care as one of only two categories with rising temporary demand is the single most important hiring signal for this sector. Commercial sales hiring sits alongside the clinical workforce — when employers defer permanent head-count growth to absorb the Iran-conflict supply-chain uncertainty, they substitute through interim consultants, contract field reps and KOL-engagement contractors rather than freezing the function entirely. Expect to spend more of the 2026 commercial sales budget on temp and contract than was typical in 2024. Time-to-permanent-hire: Territory Manager 8–12 weeks; Surgical Sales Specialist / Senior BDM 12–16 weeks; Regional Sales Manager 14–20 weeks; Commercial Director 16–24 weeks. Interim consultant placements are typically 2–4 weeks faster on the same role specs.
Force 2 — The Iran / Suez MedTech-input supply squeeze without an immediate hiring crisis. The supply-chain hit is real (25–40% Asia–Europe rate increases plus war risk surcharges; Stryker, J&J, Medtronic UK supply chains exposed), but the commercial-sales workforce is one step removed from the freight-cost shock. Expect manufacturers to absorb some of the cost upstream through price increases to NHS and private-hospital procurement, with the commercial team's job being to defend those price increases through clinical value-evidence rather than to hold volume regardless. The new pay variability for 2026 is therefore tied to product-mix shift and value-defence — bonus structures are being recalibrated quietly across multiple MedTech UK affiliates to reward clinical-outcomes evidence-building, not just unit shipment.
Force 3 — The aesthetics regulatory tightening. The Scottish Parliament's March 2026 Bill is the leading edge; the UK government licensing scheme is the main event due 2026 or 2027. Practitioners and commercial-clinical hybrid roles that can credibly navigate the new regulatory regime are commanding 10–20% pay premiums in early 2026 — the Knightsbridge Patient Coordinator £30–40K + commission ad pattern from February 2026 sits above the broader UK clinical-receptionist market for exactly this reason. The talent pool will bifurcate sharply through 2026–27: Level 7-qualified practitioner-commercials at a premium; non-medically-qualified injectors squeezed out by the licensing regime.
Force 4 — The Lorena Cosmetics rebuild reshaping aesthetics-private-pay commercial hiring. Roughly 30 clinic locations reopened from the Sk:n / Harley Medical Group ashes since December 2024, approximately 450 practitioners displaced by the July 2024 collapse partially re-absorbed across the Lorena estate (plus Therapie Clinic UK / Ireland rapid 2025–26 expansion plus doctor-led independents plus self-employed clinic models). Net effect on commercial hiring at chain level in 2026: cautious re-build mode, conservative Year 1 target attainment expectations, and a noticeable share of management-level hiring being filled by ex-Optical Express operations talent rather than by ex-Sk:n returnees.
Force 5 — The MedTech cluster pull-up at West Midlands. The cluster strength is now sufficient that London-premium-tier pay is sometimes commanded at Birmingham, narrowing the historical London / Birmingham gap. The MedTech HTQ rollout from September 2026 will increase the entry-level talent supply but is unlikely to soften Mid IC or higher cells through 2026 itself.
Healthcare, Aesthetics & MedTech is the most resilient hiring market in this guide — and the sector where the strongest candidates at Senior IC and above are rarely on the open market. Sales Recruit UK recruits across medical devices and capital equipment, pharma and biotech, aesthetics manufacturer-side, and aesthetics private-pay clinic-side at every level in this chapter — SDR / Field Clinical Specialist / Patient Coordinator, Territory Manager / Account Manager / BDM, Senior Territory Manager / MSL / Aesthetic Account Manager, Regional Sales Manager / Head of Aesthetics, and Commercial Director / VP Sales / Country Manager / CCO. We run searches across the whole of the UK and the Republic of Ireland, with concentrated networks across the M4 corridor, the Cambridge biotech cluster, the West Midlands medical-devices cluster, and the Harley Street and Glasgow aesthetics flagship corridors. See our Healthcare, Aesthetics & MedTech sales recruitment service for how we run a search, or read about our process and the SRUK Fit Score. To start a conversation, tell us about the role.
About the figures in this chapter. Each of the 35 cells above is benchmarked against a triangulation of (1) ABHI UK HealthTech sector data (£48bn turnover, 196,000 jobs, 4,360 companies) and ONS Annual Survey of Hours and Earnings (SOC 3556 percentile distribution), (2) RepVue UK Medical Device Sales Representative dataset (April 2026 update; median base ~$70K / median OTE $165K), Glassdoor UK AstraZeneca Medical Science Liaison (n=11, March 2026, median £70,633), Galderma UK National Account Manager (£83,786), Allergan Aesthetics UK Senior Manager estimate (£299,828), and PayScale and Indeed UK MedTech rep self-reports, and (3) 15+ live MedTech ads sampled through Q1–Q2 2026 across Reed, Indeed, LinkedIn, ZipRecruiter and Aesthetic Source. Aesthetics market data drawn from PolicyBee (£3.6bn 2026 forecast, 10.2% CAGR), Grand View Research, IBISWorld UK Cosmetic Surgeons Clinics, and Cosmetic College's UK Aesthetics Salary Benchmark (January 2026). Macro context drawn from KPMG/REC Report on Jobs (May 2026 issue plus January and April; Nursing / Medical / Care rising temp demand April 2026), Scottish Parliament Cosmetic Procedures (Licensing) Bill (Royal Assent March 2026), HMT Autumn Budget 2025, NIC Act 2026 (Royal Assent 29 April 2026), and the MHRA SaMD / AIaMD framework due mid-2026. The Sales Director / Commercial Director cells outside London & SE and West Midlands are flagged honestly as thin samples; benchmark these against published executive-search data rather than against the live-ad market. Read the full Methodology for the source register and sample-size detail.